Statins induce cell apoptosis through a modulation of AKT/FOXO1 pathway in prostate cancer cells

References

• Screening PDQ, Prevention Editorial B. Prostate Cancer Screening (PDQ(R)): health professional version In: PDQ Cancer Information Summaries. Bethesda (MD): National Cancer Institute (US); 2002.
   Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. doi:10.3322/caac.2155130620402
   PubMed Web of Science ®Google Scholar
• Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol. 2002;20(13):3001–3015. doi:10.1200/JCO.2002.10.01812089231
   PubMed Web of Science ®Google Scholar
• Pienta KJ, Smith DC. Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin. 2005;55(5):300–318;quiz 323–305.
   PubMed Web of Science ®Google Scholar
• Petrylak DP. New paradigms for advanced prostate cancer. Rev Urol. 2007;9(Suppl 2):S3–s12.
   PubMedGoogle Scholar
• Berry WR. The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer. Urology. 2005;65(6 Suppl):2–7. doi:10.1016/j.urology.2005.03.080
   PubMedGoogle Scholar
• LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat. 2008;11(1–2):32–50. doi:10.1016/j.drup.2007.11.00318166498
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (London, England). 2005;366(9493):1267–1278. doi:10.1016/S0140-6736(05)67394-1
   PubMed Web of Science ®Google Scholar
• Zhao SP, Peng DQ, Yu BL, Huo Y. Rationale and design of China intensive lipid lowering with statins in acute coronary syndrome: the CHILLAS study. Am Heart J. 2009;158(4):509–512.e501. doi:10.1016/j.ahj.2009.07.03019781407
   PubMed Web of Science ®Google Scholar
• Yu O, Eberg M, Benayoun S, et al. Use of statins and the risk of death in patients with prostate cancer. J Clin Oncol. 2014;32(1):5–11. doi:10.1200/JCO.2013.49.475724190110
   PubMed Web of Science ®Google Scholar
• Harshman LC, Wang X, Nakabayashi M, et al. Statin use at the time of initiation of androgen deprivation therapy and time to progression in patients with hormone-sensitive prostate cancer. JAMA Oncol. 2015;1(4):495–504. doi:10.1001/jamaoncol.2015.082926181260
   PubMed Web of Science ®Google Scholar
• Platz EA, Leitzmann MF, Visvanathan K, et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst. 2006;98(24):1819–1825. doi:10.1093/jnci/djj49917179483
   PubMedGoogle Scholar
• Mucci LA, Stampfer MJ. Mounting evidence for prediagnostic use of statins in reducing risk of lethal prostate cancer. J Clin Oncol. 2014;32(1):1–2. doi:10.1200/JCO.2013.53.277024276780
   PubMed Web of Science ®Google Scholar
• Larsen SB, Dehlendorff C, Skriver C, et al. Postdiagnosis statin use and mortality in danish patients with prostate cancer. J Clin Oncol. 2017;35(29):3290–3297. doi:10.1200/JCO.2016.71.898128806117
   PubMed Web of Science ®Google Scholar
• Raval AD, Thakker D, Negi H, Vyas A, Kaur H, Salkini MW. Association between statins and clinical outcomes among men with prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2016;19(2):151–162. doi:10.1038/pcan.2015.5826782711
   PubMed Web of Science ®Google Scholar
• Jung J, Lee C, Lee C, et al. Effects of statin use on the response duration to androgen deprivation therapy in metastatic prostate cancer. Korean J Urol. 2015;56(9):630–636. doi:10.4111/kju.2015.56.9.63026366275
   PubMedGoogle Scholar
• Matusewicz L, Meissner J, Toporkiewicz M, Sikorski AF. The effect of statins on cancer cells–review. Tumour Biol. 2015;36(7):4889–4904. doi:10.1007/s13277-015-3551-726002574
   PubMedGoogle Scholar
• Stryjkowska-Gora A, Karczmarek-Borowska B, Gora T, Krawczak K. Statins and cancers. Contemp Oncol (Pozn). 2015;19(3):167–175. doi:10.5114/wo.2014.4429426557755
   PubMedGoogle Scholar
• Zheng W, Wang H, Zeng Z, et al. The possible role of the Akt signaling pathway in schizophrenia. Brain Res. 2012;1470:145–158. doi:10.1016/j.brainres.2012.06.03222771711
   PubMed Web of Science ®Google Scholar
• Zhu GC, Yu CY, She L, et al. Metadherin regulation of vascular endothelial growth factor expression is dependent upon the PI3K/Akt pathway in squamous cell carcinoma of the head and neck. Medicine. 2015;94(6):e502. doi:10.1097/MD.000000000000087425674742
   PubMed Web of Science ®Google Scholar
• Zheng D, Zhu G, Liao S, et al. Dysregulation of the PI3K/Akt signaling pathway affects cell cycle and apoptosis of side population cells in nasopharyngeal carcinoma. Oncol Lett. 2015;10(1):182–188. doi:10.3892/ol.2015.321826170996
   PubMed Web of Science ®Google Scholar
• Tzivion G, Dobson M, Ramakrishnan G. FoxO transcription factors; Regulation by AKT and 14-3-3 proteins. Biochim Biophys Acta. 2011;1813(11):1938–1945. doi:10.1016/j.bbamcr.2011.06.00221708191
   PubMed Web of Science ®Google Scholar
• Zhang X, Tang N, Hadden TJ, Rishi AK. Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta. 2011;1813(11):1978–1986. doi:10.1016/j.bbamcr.2011.03.01021440011
   PubMed Web of Science ®Google Scholar
• Zeng Z, Wang H, Shang F, et al. Lithium ions attenuate serum-deprivation-induced apoptosis in PC12 cells through regulation of the Akt/FoxO1 signaling pathways. Psychopharmacology. 2016;233(5):785–794. doi:10.1007/s00213-015-4168-726626328
   PubMed Web of Science ®Google Scholar
• Sun H, Wang G, Peng Y, et al. H19 lncRNA mediates 17beta-estradiol-induced cell proliferation in MCF-7 breast cancer cells. Oncol Rep. 2015;33(6):3045–3052. doi:10.3892/or.2015.389925846769
   PubMed Web of Science ®Google Scholar
• Deegan S, Saveljeva S, Logue SE, et al. Deficiency in the mitochondrial apoptotic pathway reveals the toxic potential of autophagy under ER stress conditions. Autophagy. 2014;10(11):1921–1936. doi:10.4161/15548627.2014.98179025470234
   PubMed Web of Science ®Google Scholar
• Yang J, Ning J, Peng L, He D. Effect of curcumin on Bcl-2 and Bax expression in nude mice prostate cancer. Int J Clin Exp Pathol. 2015;8(8):9272–9278.26464676
   PubMed Web of Science ®Google Scholar
• Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 2006;25(34):4798–4811. doi:10.1038/sj.onc.120960816892092
   PubMed Web of Science ®Google Scholar
• Wang L, Fu P, Zhao Y, et al. Dissociation of NSC606985 induces atypical ER-stress and cell death in prostate cancer cells. Int J Oncol. 2016;49(2):529–538. doi:10.3892/ijo.2016.355527277821
   PubMed Web of Science ®Google Scholar
• Goc A, Kochuparambil ST, Al-Husein B, Al-Azayzih A, Mohammad S, Somanath PR. Simultaneous modulation of the intrinsic and extrinsic pathways by simvastatin in mediating prostate cancer cell apoptosis. BMC Cancer. 2012;12:409. doi:10.1186/1471-2407-12-40922974127
   PubMed Web of Science ®Google Scholar
• Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med. 2005;9(1):59–71. doi:10.1111/j.1582-4934.2005.tb00337.x15784165
   PubMed Web of Science ®Google Scholar
• Zaballos MA, Santisteban P. FOXO1 controls thyroid cell proliferation in response to TSH and IGF-I and is involved in thyroid tumorigenesis. Mol Endocrinol. 2013;27(1):50–62. doi:10.1210/me.2012-103223160481
   PubMedGoogle Scholar
• Yu JJ, Wu YX, Zhao FJ, Xia SJ. miR-96 promotes cell proliferation and clonogenicity by down-regulating of FOXO1 in prostate cancer cells. Med Oncol. 2014;31(4):910. doi:10.1007/s12032-014-0374-024633705
   PubMed Web of Science ®Google Scholar
• Tuteja G, Kaestner KH. Forkhead transcription factors II. Cell. 2007;131(1):192. doi:10.1016/j.cell.2007.09.01617923097
   PubMed Web of Science ®Google Scholar
• Lam EW, Francis RE, Petkovic M. FOXO transcription factors: key regulators of cell fate. Biochem Soc Trans. 2006;34(Pt 5):722–726. doi:10.1042/BST034072217052182
   PubMedGoogle Scholar
• Burgering BM, Kops GJ. Cell cycle and death control: long live Forkheads. Trends Biochem Sci. 2002;27(7):352–360.12114024
   PubMed Web of Science ®Google Scholar
• Accili D, Arden KC. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell. 2004;117(4):421–426. doi:10.1016/s0092-8674(04)00452-015137936
   PubMed Web of Science ®Google Scholar
• Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91(2):231–241. doi:10.1016/s0092-8674(00)80405-59346240
   PubMed Web of Science ®Google Scholar
• Huang H, Muddiman DC, Tindall DJ. Androgens negatively regulate forkhead transcription factor FKHR (FOXO1) through a proteolytic mechanism in prostate cancer cells. J Biol Chem. 2004;279(14):13866–13877. doi:10.1074/jbc.M31414320014726521
   PubMed Web of Science ®Google Scholar
• Modur V, Nagarajan R, Evers BM, Milbrandt J. FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J Biol Chem. 2002;277(49):47928–47937. doi:10.1074/jbc.M20750920012351634
   PubMed Web of Science ®Google Scholar
• Hu MC, Lee DF, Xia W, et al. IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell. 2004;117(2):225–237. doi:10.1016/s0092-8674(04)00302-215084260
   PubMed Web of Science ®Google Scholar
• Seoane J, Le HV, Shen L, Anderson SA, Massague J. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell. 2004;117(2):211–223. doi:10.1016/s0092-8674(04)00298-315084259
   PubMed Web of Science ®Google Scholar
• Parry P, Wei Y, Evans G. Cloning and characterization of the t(X;11) breakpoint from a leukemic cell line identify a new member of the forkhead gene family. Genes Chromosomes Cancer. 1994;11(2):79–84. doi:10.1002/gcc.28701102037529552
   PubMed Web of Science ®Google Scholar
• Galili N, Davis RJ, Fredericks WJ, et al. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet. 1993;5(3):230–235. doi:10.1038/ng1193-2308275086
   PubMed Web of Science ®Google Scholar
• Mallinson JE, Constantin-Teodosiu D, Sidaway J, Westwood FR, Greenhaff PL. Blunted Akt/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy. J Physiol. 2009;587(1):219–230. doi:10.1113/jphysiol.2008.16469919001041
   PubMed Web of Science ®Google Scholar
• Palacios F, Prieto D, Abreu C, et al. Dissecting chronic lymphocytic leukemia microenvironment signals in patients with unmutated disease: microRNA-22 regulates phosphatase and tensin homolog/AKT/FOXO1 pathway in proliferative leukemic cells. Leuk Lymphoma. 2015;56(5):1560–1565. doi:10.3109/10428194.2014.99090025430416
   PubMed Web of Science ®Google Scholar
• Allott EH, Howard LE, Cooperberg MR, et al. Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int. 2014;114(5):661–666. doi:10.1111/bju.1272024588774
   PubMed Web of Science ®Google Scholar